The U.S. Food and Drug Administration (FDA) has granted emergency use authorizations (EUAs) for COVID-19 monoclonal antibody treatment for outpatients with mild to moderate COVID-19 who are at high risk of progression to severe disease.

The following chart illustrates patient flow in a monoclonal antibody infusion facility and may be used to answer patient questions. Medication may be prepared at bedside or prepared off-site.

* Observation process may or may not happen in the infusion area and may be in another waiting area designated by the local infusion site.

**Need resource planning support?**
Visit [www.phe.gov/mAbs-calculator](http://www.phe.gov/mAbs-calculator) to use an online calculator that helps health administrators and clinicians determine and plan for resource needs to successfully ramp up treatment capacity or update existing practice.

For more information on monoclonal antibody resources, visit [CombatCOVID.hhs.gov](http://CombatCOVID.hhs.gov)